Have your say on proposed stronger labelling requirements for medicines containing vitamin B6
Peripheral neuropathy linked to vitamin B6 supplements has attracted considerable recent publicity. The TGA continues to receive reports, with 333 recorded in the Database for Adverse Events Notifications (DAEN) as at September 2026. An investigation into symptom onset and dosage found that symptoms began within one month of starting vitamin B6 in 9% of cases. Among cases with confirmed onset within three months, most involved doses of 50 mg per day or less. Many consumers were taking multiple vitamin B6 products, increasing their cumulative exposure.
Subsequently, the TGA are now proposing to strengthen the required label statements for listed medicines containing vitamin B6 and making labelling clearer so consumers can easily identify when a product contains vitamin B6 and how much. They are seeking stakeholder feedback by way of a public consultation which opened on the 14th of October.
The proposed changes include a warning statement on the main label, identifying the presence of vitamin B6 and how much, as well as varying the existing warning to simplify the wording and make its significance clearer. The proposed warning statements are:
“This medicine contains x mg (expressed as pyridoxine equivalents) vitamin B6 per [dosage unit]. Consult your healthcare practitioner if taking more than one product containing vitamin B6 and/or if using for longer than one month. (or words to that effect)”
(VITB6SX) “WARNING – Vitamin B6 may cause nerve damage. Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible.”
Additionally, the TGA are looking to reduce the dose threshold for label warnings from 10 mg to 2 mg per day of pyridoxine. This change would apply to all medicines containing vitamin B6, including the ingredients:
- pyridoxine hydrochloride
- pyridoxal 5-phosphate
- pyridoxal 5-phosphate monohydrate.
This consultation comes after an update to the Poisons Standard (to commence 1 June 2027) to include a new Schedule 3 entry for oral preparations for human therapeutic use providing more than 50 mg but less than 200 mg per day of vitamin B6. Preparations containing more than 200 mg of vitamin B6 will remain in Schedule 4, while medicines containing less than 50 mg are still permitted for retail sale.
If you have medicines containing vitamin B6 and you feel you will be impacted by the TGA’s proposal we strongly recommend that you have your voice heard and submit a response to the consultation.
More details on the consultation, including how to respond, can be found on the TGA’s consultation page
TGA Consultation for Listed Medicines Containing Vitamin B6
The consultation closes on the 25th November 2026.